AMAG Pharma (AMAG) Tops Q2 EPS by 25c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AMAG Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 9, 2016 7:31 AM EDTTotal GAAP quarterly product and service revenues increased approximately 50% to $127 million
Makena® (hydroxyprogesterone caproate injection) and Feraheme® (ferumoxytol) achieve record sales
Significant progress on next generation Makena and Feraheme development programs
Conference call scheduled for 8:00 a.m. ET today
WALTHAM, Mass., Aug. 09, 2016 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for the second quarter ended June 30, 2016. Total product and service revenues for the second quarter of 2016... More
